Primaquine is an antimalarial medication best known for its unique ability to clear dormant malaria parasites from the liver, preventing the disease from coming back weeks or months after the initial infection. It belongs to a drug class called 8-aminoquinolines and has been a cornerstone of malaria treatment for decades. Its FDA-approved use is the radical cure (complete elimination) of vivax malaria, the most widespread form of malaria worldwide.
Why Primaquine Exists
Most antimalarial drugs kill the parasites circulating in your blood, which stops the acute symptoms: fever, chills, fatigue. But two species of malaria, Plasmodium vivax and Plasmodium ovale, have a trick. After the initial mosquito bite, some parasites burrow into liver cells and go dormant. These sleeping forms, called hypnozoites, can reactivate weeks, months, or even years later and cause a full relapse of malaria, complete with fever and all the original symptoms.
No modern diagnostic test can detect whether hypnozoites are hiding in someone’s liver. That makes preventive treatment essential. Primaquine is one of only two drugs that can reach into liver cells and destroy these dormant parasites, making it irreplaceable for anyone who has had vivax or ovale malaria and wants to avoid repeated bouts of illness.
How It Works
Primaquine itself isn’t the active killer. Your liver converts it into a set of breakdown products (hydroxylated metabolites) that do the real work. These metabolites undergo a chemical reaction that generates large amounts of hydrogen peroxide, a reactive molecule toxic to malaria parasites. The process is roughly 1,000 times more potent when driven by a specific enzyme found in liver and bone marrow cells, which explains why the drug is so effective against liver-stage parasites in particular.
This liver-dependent activation is critical. A liver enzyme called CYP2D6 is responsible for converting primaquine into its active form. People who genetically produce less of this enzyme, known as “poor metabolizers,” may not activate enough of the drug for it to work properly. This genetic variation affects an estimated 5 to 10 percent of people, depending on ethnicity.
Standard Treatment Course
The World Health Organization recommends a 14-day course at 15 mg per day for adults, delivering a total dose of 210 mg. Primaquine is taken by mouth, typically alongside another antimalarial drug (like chloroquine) that handles the blood-stage infection while primaquine clears the liver.
The CDC recommends a slightly higher daily dose of 30 mg for 14 days. For people weighing over 70 kg (about 154 pounds), the CDC advises adjusting the total dose to 6 mg per kilogram of body weight, then dividing that into 30 mg daily doses spread over however many days are needed. Daily doses above 30 mg are not recommended due to safety concerns. Children can take primaquine at weight-adjusted doses after appropriate screening.
The G6PD Screening Requirement
The most important safety concern with primaquine is hemolytic anemia, a condition where red blood cells break apart faster than the body can replace them. This risk is dramatically higher in people with G6PD deficiency, a genetic condition that affects roughly 400 million people worldwide, particularly those of African, Mediterranean, Middle Eastern, and Southeast Asian descent.
G6PD is an enzyme that protects red blood cells from oxidative damage. When primaquine’s metabolites generate hydrogen peroxide (the same mechanism that kills parasites), G6PD-deficient red blood cells can’t neutralize it and rupture. Warning signs include dark-colored urine, unusual fatigue, and rapid drops in red blood cell counts. If these appear, the drug must be stopped immediately. The good news is that patients typically recover fully once the medication is discontinued.
Because of this risk, G6PD testing is required before anyone starts primaquine. People with severe G6PD deficiency should not take the drug at all. For those with intermediate deficiency levels, an alternative regimen of 45 mg once per week for eight weeks (rather than daily dosing) can sometimes be used under close monitoring. Primaquine must also not be used during pregnancy, and nursing mothers need their infants tested for G6PD deficiency before starting treatment.
Common Side Effects
For people with normal G6PD levels, primaquine is generally well tolerated, but it does cause side effects. Gastrointestinal issues are the most frequent: nausea, stomach cramps, and occasionally vomiting, especially when taken on an empty stomach. Taking the medication with food reduces these symptoms considerably.
A less common but notable side effect is methemoglobinemia, where the blood’s ability to carry oxygen is reduced. This occurs primarily in people who are deficient in a specific enzyme that keeps hemoglobin functioning normally. Symptoms can include bluish skin discoloration and shortness of breath. At standard doses in people without enzyme deficiencies, clinically significant methemoglobinemia is rare.
Drug Interactions to Know About
Because primaquine depends on the CYP2D6 enzyme for activation, any medication that blocks this enzyme can reduce primaquine’s effectiveness. The most significant interactions involve certain antidepressants. Among SSRIs and SNRIs, fluoxetine (Prozac) and paroxetine (Paxil) are the strongest inhibitors of CYP2D6 and pose the greatest risk of making primaquine less effective. Controlled experiments showed that co-administration with fluoxetine measurably altered the levels of primaquine’s active metabolites.
Other antidepressants in these classes, including citalopram, escitalopram, sertraline, and venlafaxine, are weaker inhibitors and less likely to cause problems. If you take any antidepressant and need primaquine, this interaction is worth discussing with your prescriber, since reduced activation doesn’t just mean the drug works less well. It could mean the dormant liver parasites survive and cause a relapse later.
Tafenoquine: The Newer Alternative
Tafenoquine is a newer drug in the same class as primaquine, approved for the same purpose of clearing liver-stage parasites. Its main advantage is convenience: it requires only a single dose rather than 14 days of daily pills, which makes adherence far simpler. However, tafenoquine carries the same G6PD-related risks, requires the same pre-treatment screening, and is only approved for patients 16 years and older who received chloroquine for their acute infection. Primaquine remains the more flexible option, usable in combination with any acute-phase antimalarial and available for children of all ages after G6PD screening.